医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集
▼×

幹細胞

Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period

Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period

バイオテクノロジーヘルスケア幹細胞腫瘍学製薬　 TimeLine: Commencement of Second Acceptance Period Takeda and TiGenix Announce Results of First the Voluntary and Conditional Public Takeover Bid

2018年06月06日

0

Fujifilm Completes Acquisition of Irvine Scientific Sales Company and IS Japan, Leading Companies of Cell Culture Media

Fujifilm Completes Acquisition of Irvine Scientific Sales Company and IS Japan, Leading Companies of Cell Culture Media

バイオテクノロジーヘルスケア幹細胞製薬　 TimeLine: Fujifilm Completes Acquisition of Irvine Leading Companies of Cell Culture Media

2018年06月05日

0

Research Paper Co-authored by Dr. Damien Bates, Chief Medical Officer and Head of Medical Research at SanBio Group, Published in Stroke

Research Paper Co-authored by Dr. Damien Bates, Chief Medical Officer and Head of Medical Research at SanBio Group, Published in Stroke

バイオテクノロジーヘルスケア幹細胞心臓学臨床試験製薬　 TimeLine: and Head of Medical Research at SanBio Chief Medical Officer Damien Bates Published in Stroke Research Paper Co-authored by Dr

2018年05月25日

0

AVITA Medical Announces Presentation at ISPOR Meeting Validating Acute Burn Health Economic Model

AVITA Medical Announces Presentation at ISPOR Meeting Validating Acute Burn Health Economic Model

バイオテクノロジーヘルスケアヘルス一般医療機器外科幹細胞病院臨床試験　 TimeLine: Acute Burn Health Economic Model AVITA Medical Announces Presentation at ISPOR

2018年05月22日

0

Promethera Biosciences Establishes Branch Office in Tokyo

Promethera Biosciences Establishes Branch Office in Tokyo

バイオテクノロジーヘルスケア幹細胞製薬　 TimeLine: Promethera Biosciences Establishes Branch Office

2018年05月15日

0

RECELL® Pivotal Trial in Third-Degree Burns Meets Co-Primary Endpoints and Shows Statistically Significant Reduction in Donor Skin Requirements

RECELL® Pivotal Trial in Third-Degree Burns Meets Co-Primary Endpoints and Shows Statistically Significant Reduction in Donor Skin Requirements

バイオテクノロジーヘルスケアヘルス一般外科幹細胞病院臨床試験　 TimeLine: Endpoints and Shows Statistically Significant Pivotal Trial in Third-Degree Burns Meets

2018年04月16日

0

RECELL® Study in Facial Burns Shows Excellent Cosmetic Outcomes

RECELL® Study in Facial Burns Shows Excellent Cosmetic Outcomes

バイオテクノロジーヘルスケアヘルス一般外科幹細胞病院臨床試験　 TimeLine: Study in Facial Burns Shows Excellent Cosmetic

2018年04月13日

0

ファーマブシン、FDAが多形性膠芽腫治療薬TTAC-0001を希少疾病用医薬品に指定したと発表

ファーマブシン、FDAが多形性膠芽腫治療薬TTAC-0001を希少疾病用医薬品に指定したと発表

バイオテクノロジーヘルスケア幹細胞臨床試験製薬　 TimeLine: ファーマブシン多形性膠芽腫治療薬TTAC-0001

2018年04月03日

0

PharmAbcine宣布，FDA向用于多形性胶质母细胞瘤的TTAC-0001签发孤儿药认证

PharmAbcine宣布，FDA向用于多形性胶质母细胞瘤的TTAC-0001签发孤儿药认证

バイオテクノロジーヘルスケア幹細胞臨床試験製薬　 TimeLine: FDA向用于多形性 PharmAbcine宣布

2018年04月02日

0

SanBio: Update on Development Progress of Regenerative Cell Medicine SB623

SanBio: Update on Development Progress of Regenerative Cell Medicine SB623

バイオテクノロジーヘルスケア幹細胞臨床試験製薬遺伝学　 TimeLine: Update on Development Progress of Regenerative

2018年04月02日

0